I In nf fl lu ue en nz za a: : o on ne e o or r t tw wo o m mo or re e q qu ue es st ti io on ns s
Received wisdom has it that pathogens are not generally lethal to the hosts they normally infect, because they could not survive if they were. Pathogenicity thus becomes adapted to a level at which the host survives to become reinfected (or to produce young that become infected). The most notable example of such adaptation is in the herpesviruses, which have evolved a quite extraordinary repertoire of devices for avoiding human immunity and with which most human adults in the Western world are chronically infected. Herpesviruses persist through latency. Influenza virus belongs to a different strategic class, which proliferates rapidly and escapes in coughs and sneezes, leaving the host immune. Most humans survive infection with human influenza viruses; but the adaptive truce may break down when the human viruses recombine with viruses of avian or swine origin: hence the high human mortality associated with the H5N1 avian influenza virus that emerged into public consciousness in 2005. The so-called swine H1N1 influenza virus that is the cause of the current pandemic is apparently a triplereassortant, with genes of swine, human and avian origin [2, 3] . Unlike H5N1 it is readily transmissible between humans, but it seems -so far at least -otherwise less uncouth, and in most people causes only mild disease; so perhaps in respect both of transmissibility and of pathogenicity it reflects its human rather than its swine or avian origins. What makes this virus particularly dangerous, as Peter Doherty and Stephen Turner explain in their Q&A in this issue of Journal of Biology [1] , is simply that most of us are not immune to it, and it was not, until now, on the agenda for inclusion in the seasonal influenza vaccine programme.
It is probably the level -or rather the distribution -of population immunity that also partly accounts for the atypical pattern of mortality of pandemic as against the usual seasonal influenza. Whereas seasonal influenza is more likely to kill the old, pandemic influenza (including the present H1N1 influenza) tends preferentially to kill the young. This is thought to be because older individuals are likely to have some level of immunity due to crossprotective antibodies -that is, antibodies against similar features of other, in this case past, influenza viruses [4] . (I ought however to restate that disease due to influenza A (H1N1) seems generally mild; and indeed mortality is almost certainly even lower than it seems, because it is highly likely that many infected individuals never bother to consult a doctor and the number of people actually infected therefore probably substantially exceeds the number reported.)
The options for vaccine development are discussed by Doherty and Turner; but for the coming (or in the Southern hemisphere, current) flu season, the traditional methods will have to suffice. Among the problems in developing current influenza vaccines, notoriously, is the tendency of the virus to mutate rapidly so that variants can escape detection by otherwise immune individuals (see [1] ). Influenza A (H1N1) however seems relatively homogeneous antigenically (see [3] ), and the main obstacle to rapid manufacture of the large number of doses that will be required for effective population protection is the painfully cumbersome method by which influenza vaccines are produced (see [1] Protection from influenza virus depends, as Doherty and Turner explain, on neutralizing antibodies that prevent the virus from entering cells. Recent evidence implicates intracellular components of the innate immune system, which are being recognized in increasing numbers, in the adjuvant effects of alum (see [5] ). So it seems likely that the riddle of the adjuvanticity of alum, and of the oil-and-water emulsions that may be deployed in influenza vaccines, once solved, will answer some important outstanding questions about how innate immune responses fine-tune adaptive ones.
